OrthoPediatrics (KIDS) Stock Price, News & Analysis

Company Overview

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Key Stats

• Today's Range: $19.93 to $20.41
• 50-Day Range: $20.36 to $26.31
• 52-Week Range: $19.94 to $35.99
• Volume: 119,952 shs
• Average Volume: 196,010 shs
• Market Capitalization: $489.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.83
• Consensus Rating: Moderate Buy

OrthoPediatrics Stock Analysis - MarketRank™

OrthoPediatrics scored higher than 94% of companies evaluated by MarketBeat, and ranked 66th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OrthoPediatrics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

OrthoPediatrics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OrthoPediatrics are expected to grow in the coming year, from ($0.93) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OrthoPediatrics is -16.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OrthoPediatrics is -16.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OrthoPediatrics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.99% of the float of OrthoPediatrics has been sold short.

Short Interest Ratio / Days to Cover

OrthoPediatrics has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in OrthoPediatrics has recently decreased by 0.86%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OrthoPediatrics does not currently pay a dividend.

Dividend Growth

OrthoPediatrics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.20

Percentage of Shares Shorted

6.99% of the float of OrthoPediatrics has been sold short.

Short Interest Ratio / Days to Cover

OrthoPediatrics has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in OrthoPediatrics has recently decreased by 0.86%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.76

News Sentiment

OrthoPediatrics has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for OrthoPediatrics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for KIDS on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OrthoPediatrics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $589,978.00 in company stock.

Percentage Held by Insiders

31.80% of the stock of OrthoPediatrics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.05% of the stock of OrthoPediatrics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KIDS Stock Analysis - Frequently Asked Questions

How have KIDS shares performed this year?

OrthoPediatrics' stock was trading at $23.18 at the beginning of 2025. Since then, KIDS shares have decreased by 12.7% and is now trading at $20.24.
View the best growth stocks for 2025 here.

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) issued its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.13. The firm earned $52.41 million during the quarter, compared to analyst estimates of $51.68 million. OrthoPediatrics had a negative trailing twelve-month return on equity of 5.78% and a negative net margin of 15.00%.
Read the conference call transcript.

When did OrthoPediatrics IPO?

OrthoPediatrics (KIDS) raised $52 million in an initial public offering (IPO) on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel acted as the underwriters for the IPO and William Blair and BTIG were co-managers.

Who are OrthoPediatrics' major shareholders?

Top institutional investors of OrthoPediatrics include Brown Advisory Inc. (6.71%), Wellington Management Group LLP (4.34%), Vanguard Group Inc. (3.86%) and Granahan Investment Management LLC (2.75%). Insiders that own company stock include David R Bailey, Fred Hite, Gregory A Odle, Mark C Throdahl, Daniel J Gerritzen, Joseph W Hauser, Terry D Schlotterback and Harold Ruf.
View institutional ownership trends.

How do I buy shares of OrthoPediatrics?

Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OrthoPediatrics investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/30/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:KIDS
• CIK: 1425450
• Web: www.orthopediatrics.com
• Phone: (574) 268-6379
• Fax: 574-269-3692
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $35.83
• High Stock Price Target: $50.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +77.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.97 million
• Net Margins: -15.00%
• Pretax Margin: -17.09%
• Return on Equity: -5.78%
• Return on Assets: -4.80%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 7.17
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: $212.45 million
• Price / Sales: 2.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.14 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 24,287,000
• Free Float: 16,515,000
• Market Cap: $491.57 million
• Optionable: Optionable
• Beta: 1.09